Impact of Radiofrequency Ablation and Antiarrhythmic Medications on the Quality of Life of Patients with Supraventricular Tachycardias: Preliminary Validation of the Greek Version of the Umea22 (U22) Questionnaire

Table 5

Umea22 measures at baseline and follow-up.

Measure	Item	Group	Baseline mean±SD	Follow-up mean±SD	Change mean±SD	P^∗
Well-being	01	A	2.17±2.08	6.82±2.23	4.65±3.24	<0.0001
		B	2.18±1.65	3.28±2.00	1.10±2.25	0.004
Arrhythmia frequency	08	A	2.48±1.11	0.94±0.94	-1.54±1.76	<0.0001
		B	2.38±1.27	2.18±1.03	-0.20±1.34	0.437
Arrhythmia duration	10	A	2.47±1.21	0.70±1.05	-1.77±1.54	<0.0001
		B	2.30±1.29	2.25±1.17	-0.05±1.01	0.706
Arrhythmia events affect well-being	11	A	8.00±2.15	4.14±2.67	-3.86±2.66	<0.0001
		B	7.73±2.21	8.05±1.77	0.32±2.068	0.639
Discomfort	12	A	8.18±2.04	4.21±2.84	-3.97±2.87	<0.0001
		B	8.03±2.14	8.18±1.50	0.15±2.18	0.848
Heartbeat speed	13	A	9.22±1.34	7.45±2.40	-1.77±2.264	<0.0001
		B	9.35±0.89	8.00±1.20	-1.35±1.17	<0.0001
Heartbeat intensity	14	A	9.10±1.47	7.24±2.51	-1.86±2.35	<0.0001
		B	9.23±0.89	8.08±1.12	-1.15±1.37	<0.0001
Hearbeat irregularity	15	A	6.56±3.69	4.23±3.98	-2.33±3.48	<0.0001
		B	5.73±3.73	6.08±3.10	0.35±3.59	0.907
Faint or dizziness	16	A	4.86±3.67	1.89±2.58	-2.97±3.67	<0.0001
		B	4.85±3.36	4.93±2.72	0.08±3.025	0.744
Pain	17	A	3.83±3.40	1.43±2.41	-2.40±3.50	0.041
		B	3.10±3.25	3.15±2.61	0.05±2.21	0.901
Fatigue	18	A	1.30±3.03	0.76±2.13	-0.54±2.87	<0.0001
		B	1.18±2.82	1.75±3.45	0.57±2.61	0.236
Pruritus	19	A	7.55±2.88	3.77±2.81	3.78±3.59	<0.0001
		B	7.70±2.45	7.20±2.04	-0.50±2.55	0.098
Dyspnea	20	A	4.33±3.80	1.69±2.42	-2.64±3.17	<0.0001
		B	3.78±3.28	3.43±2.80	-0.35±2.29	0.166
Personal fear	21	A	6.85±2.70	3.61±2.60	-3.23±2.62	<0.0001
		B	6.75±2.80	6.93±1.93	0.18±2.70	0.796
Fear to others	22	A	6.03±3.06	3.93±3.08	-2.08±2.83	<0.0001
		B	7.05±2.52	7.35±2.37	0.30±2.57	0.419

signed rank test.